Introduction and Objective: ADA Standards of Care recommend screening for and addressing elevated DD, yet implementation is challenging. We built a validated, 8-item screener (T1-DDAS) into EPIC in the online e-CheckIn process for adults with T1D. A positive screen for DD (>= 2.0) generates a Best Practice Advisory (BPA) notification during the clinical encounter with suggested language to discuss elevated DD and refer to a research study for evidence-based treatment. Our objective was to evaluate the extent and impact of provider engagement with the BPA.Methods: We measured provider BPA engagement for 8 weeks (10/28-12/20/24; goal = 50% engagement across all patients with DD) and subsequent patient interest in the study. Patients were contacted up to three times by research staff to enroll in the study for treatment; failure to contact was classified as ‘No response’. Those contacted were coded as ‘Interested’ vs ‘Not interested’.Results: Of N=84 encounters, 48% (n=40) of BPAs were addressed to discuss elevated DD. Provider discussion about elevated DD resulted in 69% increased interest in the study and decreased the no-response rate in recruitment efforts (Figure).Conclusion: Provider engagement with the BPA (signaling DD and its treatment was discussed in the clinic setting) increased responsiveness to subsequent contact by the research team and study enrollment among adults with T1D and elevated DD.
A. Kahkoska: None. G. Ercolino: None. L.A. Young: Research Support; Novo Nordisk, Rhythm Pharmaceuticals, Inc, Lilly Diabetes, vTv Therapeutics, Carmot Therapeutics, Inc, Insulet Corporation, Corcept Therapeutics, Diasome Pharmaceuticals, MannKind Corporation, Fractyl Health, Inc. A. Fruik: None.
American Diabetes Association (12-22-ACE-18)
Source link
Leave a Reply